Abstract
Benzoquinoid ansamycins can downregulate molecules which are chaperoned by heat shock protein (Hsp90), including numerous tyrosine kinases, steroid receptors, and cell cycle regulatory kinases. 17allylamino17demethoxygeldanamycin (17AAG) has entered the clinic, but 17dimethyl-aminoethylaminogeldanamycin (17DMA) has emerged as an analog with potential preferential pharmaceutical features.
Keywords: